TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Receives Consensus Recommendation of “Hold” from Analysts

Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) have received a consensus recommendation of “Hold” from the five ratings firms that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have given a buy recommendation to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $11.00.

TLSI has been the topic of a number of research reports. Canaccord Genuity Group lifted their price target on shares of TriSalus Life Sciences from $11.00 to $12.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. Wall Street Zen raised shares of TriSalus Life Sciences from a “sell” rating to a “hold” rating in a research report on Friday, November 28th. Zacks Research raised shares of TriSalus Life Sciences from a “strong sell” rating to a “hold” rating in a research note on Tuesday, December 16th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of TriSalus Life Sciences in a research note on Monday, December 15th.

Institutional Trading of TriSalus Life Sciences

A number of institutional investors have recently made changes to their positions in TLSI. Nantahala Capital Management LLC boosted its holdings in TriSalus Life Sciences by 2.0% during the third quarter. Nantahala Capital Management LLC now owns 2,040,245 shares of the company’s stock worth $9,487,000 after purchasing an additional 40,245 shares during the last quarter. AWM Investment Company Inc. bought a new stake in TriSalus Life Sciences during the 2nd quarter worth about $6,812,000. Vanguard Group Inc. boosted its stake in shares of TriSalus Life Sciences by 42.4% during the 3rd quarter. Vanguard Group Inc. now owns 1,159,575 shares of the company’s stock worth $5,392,000 after buying an additional 345,186 shares during the last quarter. Gilder Gagnon Howe & Co. LLC grew its holdings in shares of TriSalus Life Sciences by 32.1% in the 2nd quarter. Gilder Gagnon Howe & Co. LLC now owns 1,092,975 shares of the company’s stock valued at $5,957,000 after acquiring an additional 265,618 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in shares of TriSalus Life Sciences by 107.4% in the second quarter. Geode Capital Management LLC now owns 455,051 shares of the company’s stock valued at $2,480,000 after acquiring an additional 235,627 shares during the last quarter. Institutional investors own 2.58% of the company’s stock.

TriSalus Life Sciences Stock Down 2.7%

Shares of TLSI stock opened at $6.87 on Monday. TriSalus Life Sciences has a 12-month low of $3.42 and a 12-month high of $7.95. The firm has a fifty day moving average of $5.82 and a 200-day moving average of $5.15. The firm has a market capitalization of $343.23 million, a price-to-earnings ratio of -3.40 and a beta of 0.42.

TriSalus Life Sciences (NASDAQ:TLSI) last released its quarterly earnings data on Thursday, November 13th. The company reported ($0.96) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.79). The firm had revenue of $11.57 million during the quarter, compared to analyst estimates of $11.76 million. Research analysts expect that TriSalus Life Sciences will post -1.55 earnings per share for the current year.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.